reports
Erasca Reports Second Quarter 2025 Business Updates and Financial Resu...
Erasca Reports Second Quarter 2025 Business Updates and Financial Results Efficient execution accelerated clinical entry of pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Phase 1 monotherapy data for RAS-targeting franchise expected in 2026 Robust balance sheet with cash, cash equivalents, and marketable securities of $387 million as of June 30, 2025 is expected to fund operations into H2 2028 SAN DIEGO, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commerc...
Mission Produce® Plans Ahead for Continued Global Growth; Celebrates L...
Mission Produce® Plans Ahead for Continued Global Growth; Celebrates Legacy of Juan Wiesner, President of Central & South America Ahead of Retirement from Company and Announces Successor OXNARD, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Mission Produce, Inc. (NASDAQ: AVO) (“Mission” or “the Company”) a world leader in sourcing, producing, and distributing fresh Hass avocados, today announced that Juan Wiesner, Mission’s President of Central and South America, will retire from the Company effective November 1, 2025, following 14 years of dedicated leadership. As part of the Company’s strat...
Compass Diversified Announces Extended Forbearance
Compass Diversified Announces Extended Forbearance WESTPORT, Conn., July 28, 2025 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) ("CODI" or the “Company”) announced today that on July 25, 2025, the Company and its lender group entered into a second forbearance agreement, extending the prior forbearance period until October 24, 2025. CODI’s lenders have further increased the amount of availability on the Company's $100 million revolving credit facility, increasing it from $40 million to $60 million during the forbearance period. CODI originally entered into a forbearance agreement w...
Compass Diversified Declares Second Quarter 2025 Distributions on Seri...
Compass Diversified Declares Second Quarter 2025 Distributions on Series A, B and C Preferred Shares WESTPORT, Conn., July 02, 2025 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) (“CODI” or the “Company”), an owner of leading middle market businesses, announced today that its Board of Directors (the “Board”) has declared a quarterly cash distribution for each of its three preferred share series. This announcement underscores that in the wake of its ongoing investigation of Lugano, the Company’s diversified business model supports its continued ability to generate strong cash flow. ...
Mission Produce® Appoints Laura Flanagan to Board of Directors
Mission Produce® Appoints Laura Flanagan to Board of Directors OXNARD, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Mission Produce, Inc. (NASDAQ: AVO) (“Mission” or “the Company”), a world leader in sourcing, producing, and distributing fresh Hass avocados, today announced the appointment of Laura Flanagan to its board of directors, effective June 30, 2025. Flanagan is appointed as an independent Class III director with a term expiring at the Company’s 2026 Annual Meeting of Stockholders. In connection with this appointment, Mission Produce’s board of directors has increased the size of the...
Compass Diversified Provides an Update on its Financial Statements Ami...
Compass Diversified Provides an Update on its Financial Statements Amid the Ongoing Investigation into Lugano Holding, Inc. WESTPORT, Conn., June 25, 2025 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) (“CODI”) today disclosed non-reliance on its financial statements for fiscal years 2022 and 2023 amid an ongoing investigation into its subsidiary Lugano Holding, Inc. (“Lugano”). This follows CODI’s May 7 disclosure concerning non-reliance on its 2024 financial statements. As previously disclosed, the investigation has preliminarily identified irregularities in Lugano’s financing, ac...
- Wedbush Research
- Daniel Ives
- Sam Brandeis
- Steven Wahrhaftig
Mission Produce® Announces Fiscal 2025 Second Quarter Financial Result...
Mission Produce® Announces Fiscal 2025 Second Quarter Financial Results Achieved record fiscal second quarter revenue driven by the Marketing & Distribution segment OXNARD, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Mission Produce, Inc. (NASDAQ: AVO) (“Mission” or “the Company”) a world leader in sourcing, producing, and distributing fresh Hass avocados, today reported its financial results for the fiscal second quarter ended April 30, 2025. Fiscal Second Quarter 2025 Financial Overview: Total revenue increased 28% to $380.3 million compared to the same period last yearNet income of ...
Erasca Announces IND Clearance for Potential First-in-Class and Best-i...
Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001 Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guidance Initial Phase 1 monotherapy data for both RAS-targeting programs expected in 2026 SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced clearance ...
Erasca to Present at Upcoming Investor Conferences in June
Erasca to Present at Upcoming Investor Conferences in June SAN DIEGO, May 29, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in June 2025 and will also participate in one-on-one investor meetings at each of these conferences. Jefferies Global Healthcare Conference (June 3-5, 2025)Location: New York, NYFormat: Fireside ChatDate...
Compass Diversified Takes Action to Improve its Financial Position in ...
Compass Diversified Takes Action to Improve its Financial Position in Response to Investigation into Lugano Holding, Inc. Entered into Forbearance Agreement with Lender Group Reduced Management Fees Suspended Quarterly Distribution on Common Shares Received Notice of Late Filing from NYSE WESTPORT, Conn., May 27, 2025 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) (“CODI”) today provided an update on steps it is taking to enhance liquidity and reduce costs in the wake of its announcement that it is investigating, and has preliminarily identified irregularities in, the financing,...
MISSION PRODUCE® to Release Fiscal Second Quarter 2025 Financial Resul...
MISSION PRODUCE® to Release Fiscal Second Quarter 2025 Financial Results on Thursday, June 5, 2025 OXNARD, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Mission Produce, Inc. (NASDAQ: AVO) (“Mission” or “the Company”) a world leader in sourcing, producing, and distributing fresh Hass avocados, today announced it will release its financial results for the fiscal second quarter ended April 30, 2025 after the market closes on Thursday, June 5, 2025. The Company will host a conference call and webcast to discuss its financial results at 5:00 PM Eastern Time on the same day. Conference Call Detail...
Erasca Reports First Quarter 2025 Business Updates and Financial Resul...
Erasca Reports First Quarter 2025 Business Updates and Financial Results Early entry of RAS-targeting franchise into clinic enabled by strong execution Initial Phase 1 monotherapy data for pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 Robust balance sheet with cash, cash equivalents, and marketable securities of $411 million as of March 31, 2025 with cash runway guidance extended to H2 2028 SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developin...
Erasca Announces Early Clinical Advancement and Prioritization of RAS-...
Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway IND cleared for pan-RAS molecular glue ERAS-0015 and IND submitted for pan-KRAS inhibitor ERAS-4001, both ahead of schedule; Phase 1 monotherapy data for both programs expected in 2026 Meaningful extension of cash runway guidance from H2 2027 to H2 2028 following strategic decision to pursue partnership opportunities for naporafenib SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology co...
Moody's Ratings places Compass Group's ratings under review for downgr...
Moody's Ratings (Moody's) placed Compass Group Diversified Holdings LLC's (Compass) ratings under review for downgrade, including the Ba3 Corporate Family Rating (CFR); Ba3-PD Probability of Default Rating (PDR), and the B1 rating on the company's senior unsecured notes. Previously, the outlook was ...
Compass Diversified Discloses Non-Reliance on Financial Statements for...
Compass Diversified Discloses Non-Reliance on Financial Statements for Fiscal 2024 Amid an Ongoing Internal Investigation into its Subsidiary, Lugano Holding, Inc. The Company Intends to Delay Quarterly Earnings and Filing of 2025 Q1 Form 10-Q WESTPORT, Conn., May 07, 2025 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) (“CODI”) today disclosed non-reliance on its financial statements for fiscal 2024 amid an ongoing internal investigation into its subsidiary, Lugano Holding, Inc. It also announced that it intends to delay the filing of its first quarter 2025 Form 10-Q. The Audit...
Erasca to Present at the Bank of America Securities Health Care Confer...
Erasca to Present at the Bank of America Securities Health Care Conference SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank of America Securities 2025 Health Care Conference being held at the Encore Hotel in Las Vegas, Nevada. Management will present on Wednesday, May 14, 2025, at 2:35 pm Pacific Time and will also participate in one-on-one investor m...
Mission Produce® Appoints Michael Sims to Board of Directors
Mission Produce® Appoints Michael Sims to Board of Directors OXNARD, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Mission Produce, Inc. (NASDAQ: AVO) (“Mission” or “the Company”), a world leader in sourcing, producing, and distributing fresh Hass avocados with additional offerings in mangos and blueberries, today announced the appointment of Michael Bryan Sims to its board of directors, effective May 5, 2025. Sims is appointed as an independent Class I director, serving on the audit committee, with a term expiring at the Company’s 2028 Annual Meeting of Stockholders. In connection with this a...
Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potenti...
Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting ERAS-0015 and ERAS-4001 showed robust anti-tumor activity as monotherapy and combination therapy First-in-class examples of direct SHOC2 binders and modulators of SMP complex assembly identified with potential to block oncogenic RAS/MAPK pathway signaling SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patie...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.